Subscribe
Ahead of the 2nd International Glaucoma Symposium in Mainz, Germany, Stephan Schulz of Heidelberg Engineering outlines how the program blends everyday clinical challenges with advances in AI, imaging, and surgery.
The
The Eye Care Network caught up with Schulz to discuss the symposium’s educational goals, programme structure, and what attendees can expect to take back to their clinics.
Note: Transcript edited for clarity and length.
Schulz: When shaping the International Glaucoma Symposium 2026 agenda, we intentionally built a balanced programme that reflects both core clinical practice and the rapid evolution of technology in optic neuropathies care. The day is structured around 3 linked thematic pillars:
This format ensures that established clinical foundations—like optic neuropathy assessment and surgical decision‑making—are firmly anchored, while also integrating state‑of‑the‑art innovations such as AI applications for normative database collection, progression detection, and workflow optimisation.
The guiding principles were clinical relevance, evidence‑based insight, and future readiness. Every session was selected to deliver practical value to clinicians today (eg, identifying fast progressors, surgical toolboxes, MIGS approaches), while also inspiring attendees to thoughtfully engage with emerging tools like AI and advanced imaging workflows.
Schulz: The International Glaucoma Symposium was created to answer a clear need in education and collaboration: clinicians worldwide require a forum that bridges practical clinical decision‑making with frontier research and emerging techniques in glaucoma and optic neuropathies. Its inaugural edition in 2025 underscored this mission by focusing on the role of AI in improving detection and care pathways.
Unlike broader ophthalmology conferences, the symposium was designed to be specifically clinical‑practice driven— bringing together ophthalmologists, surgeons, and imaging experts to explore how advances in technology (especially in AI and imaging) can be translated into better patient outcomes and more confident clinical decisions. It fills the gap between high‑level research presentations and everyday clinical application, creating a bridge that empowers clinicians to innovate while maintaining strong evidence‑based care.
Schulz: That focus was central to our planning. From the opening session on practical diagnostics to dedicated talks on identifying fast progressors and interpreting imaging in optic neuropathies, the agenda is rich with everyday clinical decision points. Sessions like “Early Glaucoma – A Comprehensive Clinical Guide” and “Glaucoma Progression – Identifying Fast Progressors” are deliberately aimed at enhancing clinicians’ abilities to make accurate, timely decisions in routine care.
Likewise, the surgical block—including “Toolbox for Glaucoma Surgery,” “Trabeculectomy Revisited,” and “MIGS and other modern procedures”— was curated to address the practical realities and trade‑offs surgeons face, not just high‑theory discussions.
The goal was to ensure attendees can return to their practices with actionable approaches, clearer thresholds for intervention, and improved confidence in integrating new tools and techniques—all grounded in everyday clinical relevance.
Schulz: AI appears repeatedly across the scientific programme—from sessions on normative database collection and unsupervised learning to detecting fast progressors with AI.
Our hope is that clinicians walk away with a practical, grounded understanding of where AI fits into current clinical workflows—not as a futuristic concept, but as a real support tool for diagnosis, risk stratification, and monitoring. By combining scientific depth (eg, statistical vs AI change detection) with clinical applicability (AI tools supporting real‑time decisions), we want clinicians to evaluate, try, and integrate AI where it enhances care, while maintaining clinical judgement and patient safety at the centre.
These sessions are designed to help demystify AI, highlight real‑world successes and limitations, and encourage thoughtful adoption now, rather than relegating these technologies to a distant future.
When attendees leave Mainz, I hope 3 key takeaways resonate most:
Ultimately, we want attendees to feel empowered, inspired, and connected to the broader glaucoma care community—equipped with both practical insights and a forward‑looking view of the field’s trajectory.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
February 1, 2026
February 13-16, 2026
Rachel Simpson, MD; James Murphy, MD; Mary Qiu, MD; Jessica Steen, OD, FAAO
Rahul Tonk, MD, MBA
Sara T. Wester, MD, FACS; Cecelia Koetting, OD; Sophie Liao, MD; Jennifer Murdock, MD
Zeba A. Syed, MD
Sara T. Wester, MD, FACS; Cecelia Koetting, OD; Sophie Liao, MD; Jennifer Murdock, MD
Rachel Simpson, MD; James Murphy, MD; Mary Qiu, MD; Jessica Steen, OD, FAAO
Rahul Tonk, MD, MBA
Adrienne W. Scott, MD, FASRS; Justine Cheng, MD; Hong-Uyen Hua, MD; Sherrol A. Reynolds OD, FAAO, FNAP
Marc R. Bloomenstein, OD, FAAO; Cory J. Lappin, OD, MS, FAAO; Selina R. McGee, OD, FAAO
Laxmi V. Devisetty, MD; Rodney P. Coe, MD, MS; Majda Hadziahmetovic, MD; Xiao Yi (Ellie) Zhou, MD
David S. Liao, MD, PhD; Chang Sup Lee, MD; Douglas Matsunaga, MD; Daniel Su, MD
Adrienne W. Scott, MD, FASRS; Justine Cheng, MD; Hong-Uyen Hua, MD; Sherrol A. Reynolds OD, FAAO, FNAP
David S. Liao, MD, PhD; Chang Sup Lee, MD; Douglas Matsunaga, MD; Daniel Su, MD
Zeba A. Syed, MD
Laxmi V. Devisetty, MD; Rodney P. Coe, MD, MS; Majda Hadziahmetovic, MD; Xiao Yi (Ellie) Zhou, MD
Yasha Modi, MD; Carolyn Majcher, OD, FAAO, FORS
Yasha Modi, MD; Carolyn Majcher, OD, FAAO, FORS
David M. Brown, MD, FACS; Dilraj S. Grewal, MD
David M. Brown, MD, FACS; Dilraj S. Grewal, MD
Veeral Sheth, MD, MBA, FASRS, FACS; Mark R. Barakat, MD, FASRS; Geeta Lalwani, MD; Xiao Yi Zhou, MD
Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD
Veeral Sheth, MD, MBA, FASRS, FACS; Mark R. Barakat, MD, FASRS; Geeta Lalwani, MD; Xiao Yi Zhou, MD
Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD
Deborah Ristvedt, DO; Melissa Tawa, OD, FAAO
Melissa Barnett, OD, FAAO, FSLS, FBCLA; Cecelia Koetting, OD, FAAO, DipABO; Quan Đông Nguyễn, MD, MSc; Jennifer Li, MD
Melissa Barnett, OD, FAAO, FSLS, FBCLA; Cecelia Koetting, OD, FAAO, DipABO; Quan Đông Nguyễn, MD, MSc; Jennifer Li, MD
Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD
Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD
Tanner Ferguson, MD; Taj Nasser, MD, FWCRS
Nathan C. Steinle, MD
David A. Eichenbaum, MD
David A. Eichenbaum, MD
Nathan C. Steinle, MD
Tanner Ferguson, MD; Taj Nasser, MD, FWCRS
Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD
Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD
John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS
Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD
Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
609-716-7777
© 2025 MJH Life Sciences®
All rights reserved.
